• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

DME drug to begin phase I trial this year

Article

Vancouver-iCo Therapeutics Inc. said the FDA has accepted an investigational new drug application for iCo-007 to treat diabetic macular edema (DME).

Vancouver-iCo Therapeutics Inc. said the FDA has accepted an investigational new drug application for iCo-007 to treat diabetic macular edema (DME). The biotechnology company plans to begin its phase I clinical trial for diffuse DME during the first half of this year.

The second-generation antisense drug targets c-Raf kinase messenger RNA, potentially decreasing the edema in the retina by decreasing the signaling of various growth factors, including VEGF, which signal through the c-Raf kinase/MAP kinase pathway.

Designed and discovered by Isis Pharmaceuticals Inc., the drug was licensed to iCo Therapeutics in August 2005.

Related Videos
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
© 2024 MJH Life Sciences

All rights reserved.